Human Papillomavirus (HPV) vaccination among young adults

Medical

We currently have the knowledge and experience to prevent much of human papillomavirus (HPV)-related disease burden globally. We are already observing, in real-world settings, a decrease in vaccine-related HPV-type infections, genital warts, and cervical pre-cancers, with possible decreases in vulvar, vaginal, and anal pre-cancers, in many countries where prophylactic HPV vaccination programs have been adopted as highly effective public health programs with good vaccine coverage. Furthermore, compared to traditional cervical cytology, HPV-based screening programs now have solid evidence to support their usage as more sensitive methods of detecting underlying cervical abnormalities, which is causing a shift in the paradigms surrounding cervical screening. This article explains how preventive vaccination affects these results and the environments in which national immunization programs have used these vaccinations. There has been a global effort to guarantee that every woman has access to efficient cervical screening and every girl has the chance for primary prevention through immunization, given the achievements made so far and the accessibility of necessary resources. Given that guys are also susceptible to HPV-related malignancies, some nations have also chosen to take a gender-neutral stance by vaccinating young boys. Additionally, immunizing young boys has the benefit of lowering the infectious pool of HPV in the general population, lowering the chance of HPV transmission to sexual partners, and ultimately lowering the risk of HPV-related diseases for both sexes. Thus, it makes sense for all nations to take into account and support national policies and initiatives aimed at preventing diseases linked to HPV.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.